This study was carried out to determine the costs of SH in a population of patients with type 1 diabetes in the Spanish healthcare system and the incremental cost-effectiveness of insulin lispro over regular insulin in preventing SH episodes. Here, INS is linked to type 1 diabetes mellitus.